Molecular markers in prognosis of colorectal cancer and prediction of response to treatment

被引:21
作者
Pasche, B [1 ]
Mulcahy, M
Benson, AB
机构
[1] Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA
[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
关键词
colorectal cancer; prognosis; biomarker; TGF-beta; p21; ras; myc; p53; her-2/neu; thymidylate synthase; microsatellite instability; EGFR; p27; E-cadherin; bcl-2; CD44;
D O I
10.1053/bega.2002.0289
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Colorectal cancer is the third most common human malignancy. Direct observation and biopsy sampling by colonoscopy have provided unique opportunities to study the natural history of the disease. As a consequence, advances in the understanding of colorectal cancer pathogenesis have evolved more rapidly than with most other solid tumours, Numerous molecular events arising during the development of colorectal cancer have been sorted out over the past two decades. Despite these advances, predicting outcome and response to therapy is still a major challenge in the management of patients with colorectal cancer. Molecular and biochemical markers of colorectal cancer are greatly needed for diagnosis and prognosis as well as for the selection and monitoring of treatments. The purpose of this chapter is to provide a critical assessment of the usefulness of markers in the prognosis and prediction of response to treatment in colorectal cancer.
引用
收藏
页码:331 / 345
页数:15
相关论文
共 88 条
[41]   Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients [J].
Liu, B ;
Parsons, R ;
Papadopoulos, N ;
Nicolaides, NC ;
Lynch, HT ;
Watson, P ;
Jass, JR ;
Dunlop, M ;
Wyllie, A ;
Peltomaki, P ;
delaChapelle, A ;
Hamilton, SR ;
Vogelstein, B ;
Kinzler, KW .
NATURE MEDICINE, 1996, 2 (02) :169-174
[42]  
Liu DF, 1999, J CLIN LAB ANAL, V13, P291, DOI 10.1002/(SICI)1098-2825(1999)13:6<291::AID-JCLA7>3.3.CO
[43]  
2-B
[44]   Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas [J].
Loda, M ;
Cukor, B ;
Tam, SW ;
Lavin, P ;
Fiorentino, M ;
Draetta, GF ;
Jessup, JM ;
Pagano, M .
NATURE MEDICINE, 1997, 3 (02) :231-234
[45]  
Manne U, 2000, CLIN CANCER RES, V6, P4017
[46]  
Manne U, 1997, INT J CANCER, V74, P346, DOI 10.1002/(SICI)1097-0215(19970620)74:3<346::AID-IJC19>3.0.CO
[47]  
2-9
[48]   INACTIVATION OF THE TYPE-II TGF-BETA RECEPTOR IN COLON-CANCER CELLS WITH MICROSATELLITE INSTABILITY [J].
MARKOWITZ, S ;
WANG, J ;
MYEROFF, L ;
PARSONS, R ;
SUN, LZ ;
LUTTERBAUGH, J ;
FAN, RS ;
ZBOROWSKA, E ;
KINZLER, KW ;
VOGELSTEIN, B ;
BRATTAIN, M ;
WILLSON, JKV .
SCIENCE, 1995, 268 (5215) :1336-1338
[49]  
MARKOWITZ S, 1995, CLIN CANCER RES, V1, P441
[50]  
MAYER A, 1993, CANCER, V71, P2454, DOI 10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO